Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy.
Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Division of Vascular Medicine.
J Hypertens. 2023 Aug 1;41(8):1239-1244. doi: 10.1097/HJH.0000000000003459. Epub 2023 May 6.
Nonadherence to antihypertensive drugs (AHDs) is a major contributor to pseudo-resistant hypertension. The primary objective of this study was to determine the prevalence of nonadherence to AHDs among patients visiting the nephrology and vascular outpatient clinics.
Patients were eligible to participate in this prospective observational study if they used at least two AHDs that could be measured with a validated UHPLC-MS/MS method and had an office blood pressure at least 140 and/or at least 90 mmHg. For resistant hypertension, included patients had to use at least three AHDs including a diuretic or four AHDs. Adherence was assessed by measuring drug concentrations in blood. The complete absence of drug in blood was defined as nonadherence. A posthoc analysis was performed to determine the influence of a having a kidney transplant on the adherence rates.
One hundred and forty-two patients were included of whom 66 patients fulfilled the definition of resistant hypertension. The overall adherence rate to AHDs was 78.2% ( n = 111 patients), with the highest adherence rate for irbesartan (100%, n = 9) and lowest adherence rate for bumetanide ( n = 69%, n = 13). In further analysis, only kidney transplantation could be identified as an important factor for adherence (adjusted odds ratio = 3.35; 95% confidence interval 1.23-9.09). A posthoc analysis showed that patients with a kidney transplant were more likely to be adherent to AHDs (non-KT cohort 64.0% vs. KT-cohort 85.7%, χ 2 (2) = 10.34, P = 0.006).
The adherence rate to AHDs in hypertensive patients was high (78.2%) and even higher after a kidney transplant (85.7%). Furthermore, patients after kidney transplant had a lower risk of being nonadherent to AHDs.
抗高血压药物(AHDs)不依从是假性耐药高血压的主要原因。本研究的主要目的是确定在肾血管门诊就诊的患者中 AHD 不依从的发生率。
如果患者使用至少两种可以用经过验证的 UHPLC-MS/MS 方法测量的 AHD,且诊室血压至少为 140/90mmHg,则有资格参加这项前瞻性观察研究。对于耐药性高血压,包括必须使用至少三种 AHD 的患者,包括利尿剂或四种 AHD。通过测量血液中的药物浓度来评估依从性。血液中完全没有药物定义为不依从。进行了一项事后分析,以确定肾移植对依从率的影响。
共纳入 142 例患者,其中 66 例患者符合耐药性高血压的定义。AHD 的总体依从率为 78.2%(n=111 例),其中依那普利的依从率最高(100%,n=9 例),布美他尼的依从率最低(n=69%,n=13 例)。在进一步的分析中,只有肾移植可以被确定为依从性的一个重要因素(调整后的优势比=3.35;95%置信区间 1.23-9.09)。事后分析显示,接受肾移植的患者更有可能坚持使用 AHD(非-KT 队列 64.0%与 KT 队列 85.7%,χ2(2)=10.34,P=0.006)。
高血压患者 AHD 的依从率较高(78.2%),肾移植后更高(85.7%)。此外,肾移植后的患者不依从 AHD 的风险较低。